# Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

> **NCT00343512** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** docetaxel
- **GENETIC:** protein expression analysis
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** biopsy
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00343512
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02
- **Primary completion:** 2008-03
- **Final completion:** 2011-03
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** closed due to competing neoadjuvant studies for a small patient population
- **Last updated:** 2012-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343512, "Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00343512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*